Molecular Current Deferred Revenue from 2010 to 2026
| MOLN Stock | CHF 3.60 0.03 0.84% |
Current Deferred Revenue | First Reported 2014-12-31 | Previous Quarter 1.9 M | Current Value 585 K | Quarterly Volatility 11.7 M |
Check Molecular Partners financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Molecular Partners' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 M, Interest Expense of 41.5 K or Selling General Administrative of 12.7 M, as well as many indicators such as Price To Sales Ratio of 20.99, Dividend Yield of 0.0 or PTB Ratio of 1.07. Molecular financial statements analysis is a perfect complement when working with Molecular Partners Valuation or Volatility modules.
Molecular | Current Deferred Revenue |
The evolution of Current Deferred Revenue for Molecular Partners AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Molecular Partners compares to historical norms and industry peers.
Latest Molecular Partners' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Molecular Partners AG over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Molecular Partners' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Molecular Partners' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Molecular Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 15,970,130 | |
| Geometric Mean | 12,453,735 | |
| Coefficient Of Variation | 66.86 | |
| Mean Deviation | 8,206,293 | |
| Median | 17,841,855 | |
| Standard Deviation | 10,677,017 | |
| Sample Variance | 114T | |
| Range | 39.2M | |
| R-Value | (0.37) | |
| Mean Square Error | 105.4T | |
| R-Squared | 0.13 | |
| Significance | 0.15 | |
| Slope | (771,886) | |
| Total Sum of Squares | 1824T |
Molecular Current Deferred Revenue History
About Molecular Partners Financial Statements
Molecular Partners investors use historical fundamental indicators, such as Molecular Partners' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Molecular Partners. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 3.9 M | 3.7 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.